doi: 10.3168/jds.2009-2167
Public attitudes shifted in the post-Ozempic world, where synthetic peptide development has exploded thanks to radical advances in technology
First, it works through a completely different mechanism than stimulants, thermogenics, or GLP-1 based peptides
PMID: 9580550
GSK Headquarters: London, United Kingdom Number of employees: 65,000 Year founded: 2000 Revenue (2025): $40.1 billion Forbes overall rank: 57 GSK company reported ~31.4 billion ($41.9 billion) in annual 2025 sales driven by strong growth in its specialty medicines and vaccines portfolios, including HIV therapies such as Dovato (dolutegravir/lamivudine) and Cabenuva (cabotegravir/rilpivirine), the blockbuster RSV vaccine Arexvy (respiratory syncytial virus vaccine, adjuvanted) and expanding oncology products like Jemperli (dostarlimab-gxly)
Mendieta-Araica B, Sprndly R, Reyes-Snchez N, Sprndly E